PTPRC and leukemia: More importantly, the combined MMP14 inhibitor and cytarabine group had a significant survival advantage compared to the inhibitor or cytarabine alone (Fig. 7G), and the results showed that the inhibitor of MMP14 group reduced the leukemia burden by flow cytometric analysis of human CD45 + cells in the BM of PDX mice, the combination of the administered drug group had the lowest proportions and absolute numbers of human CD45 + cells, consistent with our findings in the mouse model of MLL-AF9 (Fig. 7H-J).